MDAI

MDAI (5,6-Methylenedioxy-2-aminoindane) is a drug that is widely used for research purposes. It is a psychoactive drug that is known for its empathogen-entactogen effects. MDAI was first developed in the 1990s by a team led by David E. Nichols at Purdue University.

History

MDAI was first synthesized in the 1990s by a team led by David E. Nichols at Purdue University. It was developed as part of a research project aimed at identifying new therapeutic agents for treating mental health disorders. The drug was found to have empathogen-entactogen effects, which led to its use in research.

Pharmacology

MDAI is a serotonin releasing agent, which means it increases the level of serotonin in the brain. This can lead to feelings of euphoria, increased sociability, and enhanced mood. However, it also has the potential to cause serotonin syndrome, a potentially life-threatening condition characterized by high body temperature, agitation, increased reflexes, tremor, sweating, dilated pupils, and diarrhea.

Legal Status

The legal status of MDAI varies by country. In some countries, it is a controlled substance, while in others it is legal to possess and use. It is important to check the legal status of MDAI in your country before purchasing or using it.

See Also

• David E. Nichols
• Psychoactive drug
• Serotonin releasing agent
• Serotonin syndrome

References

MDAI Resources
Latest articles Most recent articles Ongoing trials	Wikipedia